This Month in Ovarian Cancer

September's ovarian cancer research was full of practical questions about how to use the tools we already have. Studies refined who benefits most from PARP inhibitor maintenance, tested in a small trial whether one of them could replace chemotherapy before surgery (it could not), and looked closely at the side effects and costs of newer treatments for recurrent disease. Several papers focused on diagnosis, from ultrasound rules that help tell harmless masses from cancer to blood tests still in development, and on less common subtypes such as low-grade serous and clear cell carcinoma. For people with a BRCA mutation or a family history, there was encouraging news on genetic counseling outreach and on a preventive surgery approach that may protect quality of life. Much of the month's science was early-stage, but it adds up to steady progress toward more personalized care.

The papers highlighted here represent a selection of those published during the month. The papers were selected and summarized by AI. Accuracy of the summaries was confirmed by a scientist. This digest incorporates only open-access research articles that are free to be read by the entire community and that are explicitly licensed to be shared and reused.

PARP inhibitors and genetic testing continue to shape first-line care

PARP inhibitors, targeted drugs that block cancer cells' ability to repair their own DNA, are now a standard part of first-line care for many people with advanced ovarian cancer. This month's research looked at who benefits most and where these drugs fit.

• If you have a BRCA mutation (a gene change affecting DNA repair) or a tumor with homologous recombination deficiency, or HRD (a broader DNA-repair weakness found by tumor testing), PARP inhibitor maintenance after first-line chemotherapy offers you the clearest benefit. Feng and colleagues at The First Affiliated Hospital of Guangxi Medical University pooled seven randomized trials with 3,930 patients and found the largest improvements in time without cancer progression in these groups, including in people with HRD but no BRCA mutation. Benefit was smaller and less consistent for tumors without HRD, no single regimen clearly outperformed the others, and serious side effects were more common than with placebo. (Read the full paper)
• For people with newly diagnosed advanced ovarian cancer and HRD, standard chemotherapy remains the better choice before surgery. In cohort C of the phase 2 OPAL trial, led by Westin and colleagues at MD Anderson Cancer Center, 36 patients were randomly assigned to the PARP inhibitor niraparib or to platinum-taxane chemotherapy before interval surgery. Tumors shrank in 32% of the niraparib group versus 71% of the chemotherapy group, and this part of the trial was stopped early. Niraparib still has an established role as maintenance therapy after chemotherapy. (Read the full paper)
• The Japan Society of Gynecologic Oncology has updated its treatment guidelines for ovarian, fallopian tube, and primary peritoneal cancer, offering a useful snapshot of how expert consensus is evolving. Led by Shoji and colleagues at Iwate Medical University, the 2025 edition answers 49 clinical questions and expands guidance on HRD and genomic testing, refines when to use PARP inhibitor and bevacizumab maintenance, clarifies when a second surgery makes sense, and addresses recurrence after PARP inhibitor treatment. It also strengthens sections on fertility preservation and palliative care. (Read the full paper)
• HRD testing could become simpler if a new method holds up. Usually, HRD tests compare tumor tissue with a matched normal sample from the same person. Wang and colleagues at Henan Cancer Hospital developed a tumor-only method and found it matched the paired approach closely and identified people likely to respond to PARP inhibitors, in both Chinese and European datasets. This is a laboratory validation step, not yet a routine test. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

New targeted drugs and immunotherapies are being tested for recurrent and platinum-resistant disease

When ovarian cancer comes back, especially if it no longer responds to platinum chemotherapy, treatment options narrow. This month's research looked at newer drugs, including antibody-drug conjugates (ADCs), cancer-seeking antibodies joined to a chemotherapy payload, and immunotherapy.

• If you are receiving mirvetuximab soravtansine, an ADC that targets folate receptor-alpha for platinum-resistant ovarian cancer, eye-related side effects remain the main issue to watch for, especially in the first month. Tan and colleagues analyzed 2,582 adverse-event reports from 1,252 patients in the FDA's reporting database. Blurred vision, nerve damage, cataracts, diarrhea, abdominal pain, and lung inflammation were among the most commonly reported problems, and a few unexpected signals such as glaucoma and colitis appeared. Reporting databases can raise questions but cannot prove that a drug caused an event, so these signals need confirmation. (Read the full paper)
• A tumor's suitability for an ADC may change depending on where and when it is tested. Studying tissue from high-grade serous ovarian cancer at Charité in Berlin, Li and colleagues found that levels of ADC targets such as folate receptor-alpha varied across different parts of the same tumor and between the original tumor and later recurrences. For folate receptor-alpha, more than a third of patients would have been classified differently at recurrence than at diagnosis. The findings suggest that retesting a recent sample may matter when ADC treatment is being considered. (Read the full paper)
• Adding the immunotherapy drug pembrolizumab to weekly paclitaxel helps some people with PD-L1-positive, platinum-resistant recurrent ovarian cancer live longer, but at current prices it is costly. Using results from the KEYNOTE-B96 trial, Xuan and colleagues modeled costs in the United States and China and found the combination added about a third of a quality-adjusted year of life but was not cost-effective in either country unless the drug's price fell substantially. Analyses like this shape insurance coverage and access decisions. (Read the full paper)
• An experimental immune therapy delivered directly into the abdomen may work best by drawing in the body's own T cells. Researchers at the National Cancer Institute, led by Ning and colleagues, analyzed blood samples from a phase 1 trial of patients' own immune cells (monocytes) given with interferons into the abdomen for recurrent, platinum-resistant ovarian cancer. Long-term responders showed stronger cell-mediated immune activity, and the treatment raised chemical signals that attract T cells. This is early research that supports testing combinations with T-cell therapies. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Research is refining surgery and how doctors judge response to chemotherapy

Surgery to remove as much cancer as possible remains central to ovarian cancer treatment. This month's studies looked at a heated chemotherapy technique, how to read response to chemotherapy given before surgery, and how to reduce surgical complications.

• Heated chemotherapy washed through the abdomen during surgery, called HIPEC, is still rarely used in the United States but was linked to longer survival in a large national study. Levin and colleagues at McGill University examined nearly 16,000 people with stage III high-grade serous ovarian cancer who had surgery after chemotherapy. Only about 2% received HIPEC, although its use rose after a key 2018 trial, and median survival was 66 months with HIPEC versus about 42 to 45 months without. HIPEC also came with longer hospital stays, more readmissions, and higher 30-day mortality, and because this was not a randomized comparison, other factors may explain part of the difference. (Read the full paper)
• If you had chemotherapy before surgery, the pathology report's chemotherapy response score can help predict what lies ahead. In 157 people with advanced high-grade serous tubo-ovarian cancer, Oztosun and colleagues in Turkey found that even a partial response (score 2) was linked to longer time without recurrence and longer survival than little or no response (score 1). Median survival was about 21, 39, and 47 months for scores 1, 2, and 3. A faster drop in CA-125 and more chemotherapy cycles before surgery predicted a better response. (Read the full paper)
• Blood clots after surgery are a real risk for people with advanced ovarian cancer, especially after primary surgery. In 200 patients at Helsinki University Hospital, Salko and colleagues found that 13.6% of those who had surgery first developed a clot afterward, compared with 2.7% of those who had chemotherapy before surgery. Longer operations and liver mobilization raised the risk. Low albumin, a blood protein, was linked to shorter survival, which may help identify patients needing extra support. (Read the full paper)
• How quickly CA-125 falls during first chemotherapy, measured by a score called KELIM, may differ between populations. In a Gynecologic Cancer InterGroup analysis led by Corbaux and colleagues, patients in a Japanese trial had higher average KELIM scores than patients in Western trials, suggesting their tumors were more sensitive to chemotherapy. A favorable score predicted longer survival in both groups. The authors call for further studies of the biological and environmental reasons behind the difference. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

New blood tests and imaging rules aim to find ovarian cancer earlier and tell benign from malignant masses

There is still no proven screening test for ovarian cancer, so research is focused both on finding it earlier and on telling a harmless mass from a cancerous one.

• If you have an ovarian or adnexal mass, standardized ultrasound rules can help your doctor judge how likely it is to be cancer before surgery. In 432 women at the University of Padua, Marchetti and colleagues compared four approaches developed by the International Ovarian Tumor Analysis group and the O-RADS system. All performed very well, and the IOTA two-step strategy and the ADNEX model correctly identified more than 93% of cancers. Tools like these help doctors plan referral and surgery. (Read the full paper)
• A blood test that reads fragments of genetic material circulating in plasma, a kind of liquid biopsy, showed early promise for both detecting ovarian cancer and predicting chemotherapy resistance. Guo and colleagues at Fudan University Shanghai Cancer Center built a deep-learning model from cell-free RNA in 304 participants. It separated people with ovarian cancer from healthy controls with high accuracy in a test group and predicted platinum resistance reasonably well, although the authors caution that the resistance results are based on small numbers. The model needs testing in larger, more varied groups. (Read the full paper)
• Lipids, the fats carried in blood and in tiny particles shed by cells, may help where the standard CA-125 test falls short. Rani and colleagues found that combining lipid profiles with CA-125 distinguished borderline tumors and low-grade serous cancer from benign masses more accurately than CA-125 alone (accuracy up to 0.89 versus 0.67). The approach was especially helpful in women whose CA-125 was normal. This is early-stage diagnostic research. (Read the full paper)
• Ovarian cancer screening trials may tell us less than hoped about whether finding cancers earlier will save lives. Long and colleagues at MD Anderson showed that a common statistical method for testing "late-stage diagnosis" as a stand-in for death rates can be biased toward overly positive conclusions. Reassessing ovarian cancer screening trials, they found the completed trials give limited evidence that reducing late-stage diagnoses will translate into fewer deaths. The work matters for how future screening tests are judged. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Hereditary risk: genetic counseling, community outreach, and preventive surgery

Everyone diagnosed with ovarian cancer is advised to have genetic counseling and testing, and people with inherited risk have choices about prevention. This month's research looked at closing gaps in access and at preventive surgery that may protect quality of life.

• For premenopausal women with a BRCA1 or BRCA2 mutation, removing the fallopian tubes first and delaying removal of the ovaries may protect quality of life. In the Dutch TUBA study, led by Gootzen and colleagues at Radboudumc, 410 women chose this approach and 160 chose standard removal of both tubes and ovaries. Five years on, menopause-related quality of life was better for women who still had their ovaries, but similar once they had them removed. Removing the ovaries remains the proven way to reduce ovarian cancer risk, so this approach is an option to discuss with a specialist. (Read the full paper)
• Community health workers can bring hereditary cancer risk assessment to Spanish-speaking Hispanic and Latina women who are often missed. In California, the promotores-led Tu Historia Cuenta program, described by Montoya and colleagues at the University of California, Davis, screened 1,286 women for family history; 111 were identified as high risk and offered free genetic testing. About a third of those offered completed testing, and participants were satisfied with the process. The program also revealed new barriers, such as activating test kits and fear of future costs. (Read the full paper)
• Genetic counseling after an ovarian cancer diagnosis has become far more common, but gaps remain. In a survey of patients treated at Heidelberg University Hospital, Shaalan and colleagues found that 73% of respondents attended genetic counseling, rising from 38% in 2021 to 95% in 2025, and 28% of those tested had an inherited variant. The most common barriers were too little information, trouble scheduling appointments, and travel. If you have not yet been offered genetic counseling, it is worth asking. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Less common subtypes, including low-grade serous, clear cell, and endometriosis-associated cancers, are getting a closer look

Ovarian cancer is not one disease. This month's research looked closely at subtypes that behave differently from the more common high-grade serous form.

• If you have low-grade serous ovarian cancer, CA-125 is useful for tracking your disease but should not be relied on alone. In 368 patients from nine centers in Germany and Austria, Flethe and colleagues found that higher CA-125 at diagnosis and persistently high levels after chemotherapy were linked to worse outcomes. However, about 16% of recurrences happened while CA-125 was still normal, so imaging and symptoms remain important parts of follow-up. (Read the full paper)
• Clear cell ovarian cancer may include two distinct groups, depending on the status of a protein called p53. In 132 tumors, Hellberg and colleagues found that p53-abnormal tumors had worse outcomes, largely because they were found at later stages and were harder to remove completely. The two groups had different biomarker patterns, which could eventually guide more tailored treatment. (Read the full paper)
• Cancers that arise from endometriosis usually have a better outlook, but platinum resistance changes that. In 224 patients in Taiwan, Sung and colleagues found that endometriosis-associated cancers (clear cell or endometrioid) were diagnosed younger and earlier and had better survival overall. Yet no patient with platinum-resistant endometriosis-associated cancer survived beyond five years, underscoring the need for better treatments for resistant clear cell disease. (Read the full paper)
• If you have endometriosis, your relative risk of ovarian cancer is higher, but your absolute risk remains low. Pooling 67 studies, Piacenti and colleagues found that endometriosis was linked to about 1.6 to 3 times the risk of ovarian cancer, mostly clear cell and endometrioid types. Cancers linked to endometriosis tended to be found earlier and carried better survival. The authors call for better ways to identify which women with endometriosis need closer monitoring. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Survivorship research looks at life during and after treatment

Living with and after ovarian cancer brings physical and emotional challenges. This month's open-access research in this area focused on menopause after treatment.

• Many survivors of epithelial ovarian cancer may be able to use menopausal hormone therapy safely to relieve symptoms such as hot flashes, vaginal dryness, and sleep problems. A position paper from the FIGO Committee on Women at Menopausal Age, led by da Silva-Filho and colleagues, reviewed evidence across gynecologic cancers and concluded that systemic hormone therapy may suit carefully chosen survivors of cancers that are not hormone-dependent, including most epithelial ovarian cancers. People with hormone-sensitive tumors should generally avoid it, and vaginal or non-hormonal options remain important. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

Epidemiology, Access & Health Disparities Research

These studies track who develops ovarian cancer, how outcomes are changing, and where the burden falls most heavily.

• Ovarian cancer in adolescents and young adults is diagnosed at similar rates around the world, but young women in lower-income countries are more likely to die from it. Using international cancer databases, Du and colleagues found that low Human Development Index regions had the highest death rates despite lower incidence, pointing to gaps in access to diagnosis and treatment. (Read the full paper)
• For younger women in the Nordic countries, ovarian cancer has become less common and more survivable. Using registry data for women under 50 from 1980 to 2023, Riese and colleagues at the Karolinska Institutet found that ovarian cancer incidence halved, death rates fell by 75%, and five-year relative survival rose from 48-64% to 68-81%. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

General & Basic-Science Research

This month's laboratory and early translational research is listed here so researchers can find it. Two preclinical studies stood out for their potential to address drug resistance.

• A new drug class may help when ovarian cancer stops responding to platinum chemotherapy. Pellarin and colleagues at the CRO Aviano National Cancer Institute in Italy found that blocking enzymes called CDK12 and CDK13 made platinum more effective in many laboratory models and delayed resistant recurrence. A clinical-grade inhibitor, CT7439, which is now in phase I/II trials, confirmed the effect. These are preclinical findings. (Read the full paper)
• Researchers may have found a way to overcome resistance to PARP inhibitors. Venkatachalam and colleagues at Mayo Clinic showed that PARP inhibitors push some cancer cells into senescence, a dormant-like state, and these cells persist as resistance develops. Adding a drug that blocks the survival protein BCL-XL reduced resistance in cell lines and improved tumor response in a mouse model built from a patient's resistant tumor. This is preclinical work that supports future trials. (Read the full paper)

Check the citations section for a comprehensive list of publications associated with this topic.

What Does This Mean for Me?

If you are newly diagnosed. Ask whether your tumor has been tested for BRCA mutations and HRD, because these results strongly shape whether PARP inhibitor maintenance is likely to help you. If you are having chemotherapy before surgery, your pathology report may include a chemotherapy response score, which you can ask your team to explain. Genetic counseling is recommended for everyone with ovarian cancer; if it has not been offered, ask for a referral. A good question for your care team: "What do my tumor and genetic test results mean for my maintenance options?"

If your cancer has come back. Newer treatments such as antibody-drug conjugates and immunotherapy combinations are expanding options for recurrent and platinum-resistant disease. If you are offered mirvetuximab soravtansine, ask how your eyes will be monitored, especially early in treatment. Because target levels can change over time, ask whether testing a recent tumor sample might help guide treatment choices, and whether a clinical trial could be right for you.

If you carry a BRCA mutation or have a strong family history. Preventive surgery remains the most effective way to lower ovarian cancer risk. If you are premenopausal and worried about early menopause, ask a specialist whether removing the fallopian tubes first and delaying removal of the ovaries might be an option for you, and what the trade-offs are. Free or low-cost community testing programs exist in some areas, and genetic counselors can help you weigh your choices.

Clinical trials are how every advance described here became possible. Ask your care team whether a trial might be right for you, or explore options at ClinicalTrials.gov. OCRA's patient support programs and resources at ocrahope.org can help you find information, connect with others, and navigate care.

---

This digest is prepared by OCRA (Ovarian Cancer Research Alliance) for patients, caregivers, and advocates. It is intended to inform, not to guide individual treatment decisions. Please speak with your care team about what research findings may mean for your specific situation.

Sources

The citations below are grouped to match the sections above. "Directly referenced" papers are the ones summarized in that section; the remaining entries are on-topic papers that were either not discussed above or are behind access restrictions.

PARP inhibitors and genetic testing continue to shape first-line care

Directly referenced:

1. Feng J, et al. "PARP inhibitor-based first-line maintenance therapy for newly diagnosed advanced ovarian cancer across molecular subgroups: an updated systematic review and network meta-analysis." Front Oncol. September 18, 2026. PMID 42827527. https://doi.org/10.3389/fonc.2026.1884407

2. Westin SN, et al. "Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial." Gynecol Oncol. September 2026. PMID 42623963. https://doi.org/10.1016/j.ygyno.2026.07.023

3. Shoji T, et al. "Guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer: 2025 edition by the Japan Society of Gynecologic Oncology." J Gynecol Oncol. September 11, 2026. PMID 42800706. https://doi.org/10.3802/jgo.2026.37.e150

4. Wang Z, et al. "Development of an homologous recombination deficiency scoring algorithm for unmatched ovarian tumor sample based on next-generation sequencing." J Gynecol Oncol. September 2026. PMID 41995271. https://doi.org/10.3802/jgo.2026.37.e97

Additional open-access citations:

5. Zou D, et al. "A retrospective analysis of adverse drug reaction case reports for PARP inhibitors: a comparative study of olaparib and niraparib." Front Pharmacol. September 24, 2026. PMID 42851666. https://doi.org/10.3389/fphar.2026.1935594 (open access, PARP inhibitor side-effect case reports)

6. Deng O, et al. "Integrative proteomics reveals MSH6 to modulate PARP inhibitor sensitivity in BRCA1/2-proficient ovarian cancer." PLoS One. September 2, 2026. PMID 42685115. https://doi.org/10.1371/journal.pone.0357365 (open access, PARP inhibitor sensitivity in BRCA-normal tumors, laboratory study)

7. Hanna K, et al. "Homologous recombination-deficient high-grade serous ovarian cancers exhibit distinct morphological features." Int J Gynecol Cancer. September 2026. PMID 42091345. https://doi.org/10.1016/j.ijgc.2026.104690 (open access, tumor appearance linked to HRD status)

8. Pawul W, et al. "Prognostic and therapeutic implications of BRCA1 and BRCA2 mutations in ovarian cancer." Front Oncol. September 8, 2026. PMID 42774753. https://doi.org/10.3389/fonc.2026.1899836 (open access, review of BRCA1/2 and outcomes)

9. Ammous-Boukhris N, et al. "A Novel BRCA1 Pathogenic Variant in Tunisian Patient With High Grade Ovarian Cancer: Favorable Therapeutic Response to Olaparib." Cancer Rep (Hoboken). September 2026. PMID 42693633. https://doi.org/10.1002/cnr2.70658 (open access, case report, new BRCA1 variant)

10. Camps-Fajol C, et al. "Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation." Signal Transduct Target Ther. September 23, 2026. PMID 42778539. https://doi.org/10.1038/s41392-026-02954-4 (open access, review of synthetic lethality and PARP inhibitors)

Related citations, access restricted:

11. Vergote I, et al. "Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial." Lancet Oncol. September 7, 2026. PMID 42705254. https://doi.org/10.1016/S1470-2045(26)00223-8 (subscription access)

12. Tang WJ, et al. "Olaparib as the first-line maintenance therapy in advanced-stage epithelial ovarian cancer patients with BRCA mutations - Real-world experience from Taiwan." Taiwan J Obstet Gynecol. September 2026. PMID 42642151. https://doi.org/10.1016/j.tjog.2025.01.016 (restricted license, CC BY-NC-ND 4.0)

13. Namozova F, et al. "Olaparib maintenance versus placebo or standard of care in ovarian cancer: a biomarker-driven systematic review and meta-analysis of randomized trials." Int J Clin Oncol. September 2026. PMID 42550402. https://doi.org/10.1007/s10147-026-03144-6 (subscription access)

14. Salutari V, et al. "Intermittent olaparib with neoadjuvant platinum-based chemotherapy in BRCA-mutated un-resectable ovarian cancer: the NUVOLA trial." Int J Gynecol Cancer. September 2026. PMID 42435644. https://doi.org/10.1016/j.ijgc.2026.104816 (license unconfirmed)

15. Gertych W, et al. "Age-related distribution of homologous recombination deficiency in advanced ovarian carcinoma: a large real-world French cohort." Int J Gynecol Cancer. September 2026. PMID 42462286. https://doi.org/10.1016/j.ijgc.2026.104821 (subscription access)

16. Banda K, et al. "HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic Implications." Clin Cancer Res. September 1, 2026. PMID 42201779. https://doi.org/10.1158/1078-0432.CCR-25-1629 (free to read, no reuse license)

17. Muiz F, et al. "Clinicopathological Correlation of BRCA1 Status in High‑Grade Serous Ovarian Carcinoma via IHC and NGS." Asian Pac J Cancer Prev. September 1, 2026. PMID 42808387. https://doi.org/10.31557/APJCP.2026.27.9.3213 (license unconfirmed)

18. Russo G, et al. "The impact of BRCA status on the efficacy of paclitaxel monotherapy in recurrent ovarian cancer." Int J Gynecol Cancer. September 2026. PMID 41946649. https://doi.org/10.1016/j.ijgc.2026.104641 (subscription access)

19. Lei M, et al. "The emerging landscape of polymerase θ in tumor pathogenesis and precision treatment." Biochem Biophys Res Commun. September 15, 2026. PMID 42748573. https://doi.org/10.1016/j.bbrc.2026.154593 (subscription access)

New targeted drugs and immunotherapies are being tested for recurrent and platinum-resistant disease

Directly referenced:

20. Tan H, et al. "Post-marketing safety assessment of mirvetuximab soravtansine: a disproportionality analysis based on the FDA Adverse Event Reporting System." J Gynecol Oncol. September 3, 2026. PMID 42750304. https://doi.org/10.3802/jgo.2027.38.e27

21. Li X, et al. "Spatial, temporal, and molecular heterogeneity of ADC targets in high-grade serous ovarian carcinoma." Br J Cancer. September 2026. PMID 42231029. https://doi.org/10.1038/s41416-026-03482-2

22. Xuan F, et al. "Cost-effectiveness of pembrolizumab plus weekly paclitaxel for PD-L1-positive platinum-resistant recurrent ovarian cancer in the United States and China." Front Pharmacol. September 21, 2026. PMID 42835177. https://doi.org/10.3389/fphar.2026.1926275

23. Ning F, et al. "Transcriptomic analysis of a phase 1 trial for intraperitoneal monocytes plus IFNs in ovarian cancer reveals support and recruitment of cell-mediated immunity." J Immunother Cancer. September 7, 2026. PMID 42705863. https://doi.org/10.1136/jitc-2026-014938

Additional open-access citations:

24. Joseph L, et al. "Biomarker-Driven Treatments for Ovarian Cancer: Moving Beyond HRD?" Int J Womens Health. September 26, 2026. PMID 42824309. https://doi.org/10.2147/IJWH.S571328 (open access, review of biomarker-driven treatments beyond HRD)

25. Yokosu K, et al. "Changes and clinical impact of HER3 andexpression in primary and recurrent ovarian cancer." J Gynecol Oncol. September 11, 2026. PMID 42750306. https://doi.org/10.3802/jgo.2027.38.e30 (open access, HER2 and HER3 changes at recurrence)

26. Gül G, et al. "Tumour-Stroma Ratio and Platinum Resistance in Epithelial Ovarian Cancer: An Exploratory Analysis." Cancers (Basel). September 5, 2026. PMID 42738396. https://doi.org/10.3390/cancers18172876 (open access, tumor-stroma ratio and platinum resistance)

27. Petta TB, et al. "Age as a biological stratifier for immune checkpoint inhibitor response in ovarian cancer." Res Sq. September 14, 2026. PMID 42779970. https://doi.org/10.21203/rs.3.rs-10655967/v1 (open access, age and immunotherapy response, preprint)

28. Gupta MK, et al. "Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer." MedComm (2020). September 25, 2026. PMID 42798783. https://doi.org/10.1002/mco2.71009 (open access, review of mesothelin-targeted immunotherapy)

29. Epp A, et al. "Multimodal characterization of HLA-G expression across solid tumors reveals transcript-protein discordance and implications for immunotherapy targeting." Front Immunol. September 24, 2026. PMID 42851436. https://doi.org/10.3389/fimmu.2026.1876556 (open access, HLA-G expression across solid tumors)

30. Henderson BD, et al. "A workflow for assessing antibody-drug conjugate target expression on circulating tumour cells from triple-negative breast cancer and epithelial ovarian cancer patients." J Liq Biopsy. September 2026. PMID 42433605. https://doi.org/10.1016/j.jlb.2026.100479 (open access, ADC targets on circulating tumor cells)

31. Vegter M, et al. "Patient-derived organoids as predictor of clinical response in ovarian cancer: a systematic review." Transl Oncol. September 6, 2026. PMID 42702147. https://doi.org/10.1016/j.tranon.2026.103017 (open access, organoids as predictors of treatment response, systematic review)

32. Yang X, et al. "Spatiotemporal immune heterogeneity and precision immunotherapy for ovarian cancer." Clin Transl Med. September 2026. PMID 42735911. https://doi.org/10.1002/ctm2.70836 (open access, review of immune heterogeneity and immunotherapy)

Related citations, access restricted:

33. Manning WB, et al. "IMMU-NO versus yes: Applicability of immune checkpoint inhibitors in gynecologic cancers." Cancer. September 15, 2026. PMID 42745396. https://doi.org/10.1002/cncr.70611 (free to read, no reuse license)

34. Veneziani AC, et al. "The evolving role of immunotherapy in ovarian cancer." Cancer. September 15, 2026. PMID 42723498. https://doi.org/10.1002/cncr.70581 (restricted license, CC BY-NC-ND 4.0)

35. Singh B, et al. "Folate receptor-α targeted therapies in ovarian cancer: recent advances and emerging therapeutic strategies." Int Immunopharmacol. September 2026. PMID 42322854. https://doi.org/10.1016/j.intimp.2026.117042 (subscription access)

36. Shan Y, et al. "Clinical landscape of therapeutic vaccines for ovarian cancer: current status, challenges, and future directions." J Ovarian Res. September 10, 2026. PMID 42778941. https://doi.org/10.1186/s13048-026-02253-0 (restricted license, CC BY-NC-ND 4.0)

37. Jones AV, et al. "Real-world outcomes after Mirvetuximab Soravtansine treatment for recurrent ovarian Cancer: Results from a university setting." Gynecol Oncol Rep. September 1, 2026. PMID 42733650. https://doi.org/10.1016/j.gore.2026.102197 (restricted license, CC BY-NC-ND 4.0)

38. Krivenko O, et al. "HER2-directed therapy with Trastuzumab deruxtecan in recurrent mucinous ovarian carcinoma: complete clinical response and response to rechallenge." Gynecol Oncol Rep. September 11, 2026. PMID 42781458. https://doi.org/10.1016/j.gore.2026.102205 (restricted license, CC BY-NC-ND 4.0)

39. Lheureux S, et al. "BEHOLD-1 and -2: phase 1/2 randomized studies evaluating the B7 homolog 4 protein-targeted antibody-drug conjugate mocertatug rezetecan in patients with solid tumors, including endometrial and ovarian cancers." Int J Gynecol Cancer. September 7, 2026. PMID 42850140. https://doi.org/10.1016/j.ijgc.2026.105607 (subscription access)

40. Guo J, et al. "PiggyBac-Engineered Membrane-Bound IL7 TILs Combined with Anti-PD-1 Antibody Demonstrates Efficacy in Recurrent Ovarian Cancer: A First-in-Human Phase I Trial." Clin Cancer Res. September 1, 2026. PMID 42189877. https://doi.org/10.1158/1078-0432.CCR-25-4130 (license unconfirmed)

41. Blair HA. "Relacorilant: First Approval." Drugs. September 2026. PMID 42334771. https://doi.org/10.1007/s40265-026-02351-9 (subscription access)

42. Zhang Y, et al. "Deep learning of pretreatment ascites cytopathology for platinum-resistance risk stratification in advanced epithelial ovarian cancer." Neoplasia. September 2026. PMID 42365738. https://doi.org/10.1016/j.neo.2026.101330 (license unconfirmed)

43. Xu Z, et al. "PD-L1 in Ovarian Cancer: Immune Evasion, Tumor-Intrinsic Signaling, and Chemoresistance." Cancer Med. September 2026. PMID 42755018. https://doi.org/10.1002/cam4.72296 (license unconfirmed)

44. Rajapaksha W, et al. "Receptor Co‑targeting Strategies for Personalized Ovarian Cancer Therapy." Int J Nanomedicine. September 7, 2026. PMID 42732377. https://doi.org/10.2147/IJN.S633450 (free to read, no reuse license)

45. Long W, et al. "Natural killer cells in ovarian cancer therapy: mechanisms, evasion, and therapeutic innovations." Inflammopharmacology. September 17, 2026. PMID 42753071. https://doi.org/10.1007/s10787-026-02397-x (subscription access)

46. Chigusa N, et al. "Biopsy-proven kidney-limited thrombotic microangiopathy associated with bevacizumab and pegylated liposomal doxorubicin: a case with a biphasic clinical course." CEN Case Rep. September 2, 2026. PMID 42684642. https://doi.org/10.1007/s13730-026-01175-6 (free to read, no reuse license)

47. Macchia G, et al. "Challenges in the use of the European Society for Radiotherapy and Oncology-European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer." Lancet Oncol. September 2026. PMID 42636843. https://doi.org/10.1016/S1470-2045(26)00296-2 (subscription access)

48. Wimberger P, et al. "[Update on ovarian cancer]." Pathologie (Heidelb). September 28, 2026. PMID 42803933. https://doi.org/10.1007/s00292-026-01596-1 (subscription access)

49. Edwards CC, et al. "A phase II study in newly diagnosed stage III/IV epithelial ovarian cancer evaluating carboplatin/taxol/pembrolizumab in patients receiving neoadjuvant chemotherapy followed by pembrolizumab maintenance with or without olaparib." Gynecol Oncol. September 21, 2026. PMID 42767168. https://doi.org/10.1016/j.ygyno.2026.09.002 (subscription access)

Research is refining surgery and how doctors judge response to chemotherapy

Directly referenced:

50. Levin G, et al. "From evidence to practice: national patterns of hyperthermic intra-peritoneal chemotherapy use and survival in advanced ovarian cancer." Int J Gynecol Cancer. September 2026. PMID 42248788. https://doi.org/10.1016/j.ijgc.2026.104762

51. Oztosun B, et al. "Chemotherapy Response Score and Survival Outcomes After Neoadjuvant Chemotherapy in High-Grade Serous Tubo-Ovarian Carcinoma: A Multicenter Retrospective Study." Medicina (Kaunas). September 3, 2026. PMID 42796295. https://doi.org/10.3390/medicina62091688

52. Salko M, et al. "Post-operative venous thromboembolism in advanced epithelial ovarian cancer: risk factors, tumor gene expression, and survival." Int J Gynecol Cancer. September 2026. PMID 42442219. https://doi.org/10.1016/j.ijgc.2026.104818

53. Corbaux P, et al. "Differences in first-line chemosensitivity assessed by ELIMination rate constant K in advanced serous ovarian cancer: evidence from Western and Japanese Trials in a Gynecologic Cancer InterGroup meta-analysis." Int J Gynecol Cancer. September 2026. PMID 42425044. https://doi.org/10.1016/j.ijgc.2026.104805

Additional open-access citations:

54. Nagano H, et al. "Significance of peritoneal washing cytology as a predictive factor for the long-term benefit of secondary debulking surgery in ovarian cancer." J Gynecol Oncol. September 2026. PMID 41958173. https://doi.org/10.3802/jgo.2026.37.e94 (open access, washing cytology and secondary debulking)

55. Yabuno A, et al. "Direct comparison of 5-aminolevulinic acid photodynamic diagnosis and white light inspection for detecting peritoneal dissemination in advanced ovarian cancer: a pilot study." J Gynecol Oncol. September 2026. PMID 41863234. https://doi.org/10.3802/jgo.2026.37.e85 (open access, 5-ALA fluorescence to detect peritoneal spread, pilot)

56. Acs M, et al. "The evolving role of open abdominal surgery in gynecological malignancies in the era of minimally invasive and precision oncology." World J Surg Oncol. September 7, 2026. PMID 42706566. https://doi.org/10.1186/s12957-026-04510-4 (open access, review of open surgery in gynecologic cancers)

57. Reifenhaeuser S, et al. "Altered ANG/TIE gene expression in advanced ovarian cancer is not accompanied by disproportionate body water accumulation relative to perioperative fluid balance." Sci Rep. September 1, 2026. PMID 42680803. https://doi.org/10.1038/s41598-026-68951-3 (open access, fluid balance after cytoreductive surgery)

58. Corbaux P, et al. "Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial." Transl Oncol. September 2026. PMID 42385345. https://doi.org/10.1016/j.tranon.2026.102896 (open access, circulating nucleosomes during neoadjuvant chemotherapy)

59. Lüchtenborg AM, et al. "Management of skin metastases of ovarian cancer: a novel therapeutic approach." Strahlenther Onkol. September 2026. PMID 42126534. https://doi.org/10.1007/s00066-026-02546-9 (open access, case report, skin metastases treated with hyperthermia and radiotherapy)

Related citations, access restricted:

60. Ray MD, et al. "Performing right upper abdominal cytoreduction: anatomical planes, liver mobilization and occult spaces." J Egypt Natl Canc Inst. September 11, 2026. PMID 42726425. https://doi.org/10.1186/s43046-026-00410-6 (free to read, no reuse license)

61. Petrella F, et al. "Segmental sternal resection for metastatic ovarian cancer: surgical technique and clinical outcome." Multimed Man Cardiothorac Surg. September 29, 2026. PMID 42808208. https://doi.org/10.1510/mmcts.2026.087 (subscription access)

62. Ainio C, et al. "Predicting residual disease and extent of surgery after neoadjuvant chemotherapy for ovarian cancer: Does the MSKCC model from the primary setting apply?" Gynecol Oncol. September 2026. PMID 42612479. https://doi.org/10.1016/j.ygyno.2026.08.011 (subscription access)

63. Matsuo K, et al. "Adnexectomy without intraoperative capsule rupture for early ovarian cancer: survival comparison between minimally invasive and open surgery." Int J Gynecol Cancer. September 2026. PMID 42526141. https://doi.org/10.1016/j.ijgc.2026.104871 (subscription access)

64. Chu R, et al. "Pre-operative Nutritional Risk Screening 2002-based nomograms for predicting post-operative complications after cytoreductive surgery for ovarian cancer: a multi-center retrospective cohort study." Int J Gynecol Cancer. September 2026. PMID 42497581. https://doi.org/10.1016/j.ijgc.2026.104832 (subscription access)

65. Hu W, et al. "Preoperative nutritional risk and clinically relevant postoperative complications in ovarian cancer patients undergoing cytoreductive surgery." Surg Oncol. September 26, 2026. PMID 42804941. https://doi.org/10.1016/j.suronc.2026.102579 (subscription access)

66. Xie J, et al. "Etomidate combined with TAPB in ovarian cancer surgery: A controlled study on hemodynamics and immune response." Pak J Pharm Sci. September 2026. PMID 42437334. https://doi.org/10.36721/PJPS.2026.39.9.268.1 (license unconfirmed)

67. Klasa-Mazurkiewicz D, et al. "Reframing response in neoadjuvant chemotherapy for ovarian cancer: Integrating molecular and functional biomarkers." Crit Rev Oncol Hematol. September 2026. PMID 42437630. https://doi.org/10.1016/j.critrevonc.2026.105488 (license unconfirmed)

68. Bruno M, et al. "Predictive Features Specific to FIGO IIIA1 Ovarian Cancer: What Drives Prognosis." Ann Surg Oncol. September 2026. PMID 42230470. https://doi.org/10.1245/s10434-026-19895-5 (license unconfirmed)

69. Prost P, et al. "The prognostic impact of celiac lymph node involvement in advanced ovarian cancer." Int J Gynecol Cancer. September 2026. PMID 42225543. https://doi.org/10.1016/j.ijgc.2026.104653 (subscription access)

70. Helpman L, et al. "Oral anticoagulants reduce venous thromboembolism rates in patients on 1st-line treatment for ovarian Cancer- A quality improvement project." Gynecol Oncol. September 2026. PMID 42561468. https://doi.org/10.1016/j.ygyno.2026.07.018 (subscription access)

71. Ricotta G, et al. "Approach to the hepato-gastric region in gynecological malignancies." Int J Gynecol Cancer. September 2026. PMID 42414127. https://doi.org/10.1016/j.ijgc.2026.104801 (subscription access)

72. Bahrehmand K, et al. "[The role of sentinel lymph node biopsy in the management of gynecologic cancers: current evidence and institutional experience]." Magy Onkol. September 2026. PMID 42731005. https://pubmed.ncbi.nlm.nih.gov/42731005/ (free to read, no reuse license)

73. No authors listed. "[Expert consensus on cytopathological examination of intraoperative peritoneal effusion or pelvic/peritoneal washing for gynecological neoplasms]." Zhonghua Bing Li Xue Za Zhi. September 8, 2026. PMID 42706107. https://doi.org/10.3760/cma.j.cn112151-20260223-00131 (license unconfirmed)

74. Xie NW, et al. "Splenic Granulomatous Lesions Mimicking Metastases on 18 F-FDG PET/CT in a Patient With Ovarian Cancer." Clin Nucl Med. September 2026. PMID 42537211. https://doi.org/10.1097/RLU.0000000000006572 (subscription access)

New blood tests and imaging rules aim to find ovarian cancer earlier and tell benign from malignant masses

Directly referenced:

75. Marchetti M, et al. "External Validation of the IOTA Two-Step Strategy for Pre-operative Characterization of Adnexal Masses: Comparison with ADNEX, O-RADS and a Sequential Simple Rules-ADNEX Approach." Int J Gynecol Cancer. September 2026. PMID 42470722. https://doi.org/10.1016/j.ijgc.2026.104824

76. Guo Q, et al. "Ovarian Cancer Diagnosis and Chemoresistance Prediction Model Based on cfRNA Molecular Signature." Adv Sci (Weinh). September 2026. PMID 42467997. https://doi.org/10.1002/advs.76274

77. Rani S, et al. "Small Extracellular Vesicle and Total Lipid Profiles Provide a Diagnostic Advantage Over CA-125 Across Ovarian Cancer Subtypes." J Extracell Vesicles. September 2026. PMID 42680694. https://doi.org/10.1002/jev2.70348

78. Long JP, et al. "Bias in Meta-Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials." Stat Med. September 2026. PMID 42705867. https://doi.org/10.1002/sim.70731

Additional open-access citations:

79. Karlsen NS, et al. "Clinical use of the IOTA terminology in routine clinical practice and its impact on diagnostic performance and calibration of the ADNEX model and two-step strategy: A Danish prospective multicenter cohort study." J Gynecol Obstet Hum Reprod. September 2026. PMID 41999885. https://doi.org/10.1016/j.jogoh.2026.103193 (open access, IOTA ultrasound terminology in routine practice)

80. Feng W, et al. "Application of Serum CA125, HE4, ROMA, and CPH-I in the Preoperative Differentiation of Ovarian Tumors: A Diagnostic Accuracy Study." J Clin Lab Anal. September 2026. PMID 42578276. https://doi.org/10.1002/jcla.70319 (open access, serum markers for ovarian tumor diagnosis)

81. Xu S, et al. "Clinical Value of an LDH-CA125-NLR Panel for Diagnosis, Platinum Resistance, and Prognostic Assessment in Epithelial Ovarian Cancer." Curr Oncol. September 10, 2026. PMID 42782897. https://doi.org/10.3390/curroncol33090551 (open access, LDH-CA125-NLR blood panel)

82. Bisht D, et al. "Liquid biopsy-based diagnostic evaluation of hypermethylated CpG sites for ovarian cancer diagnosis." Mol Oncol. September 2026. PMID 42299856. https://doi.org/10.1002/1878-0261.70277 (open access, DNA methylation blood test, pilot)

83. Leow JY, et al. "DNA methylation biomarkers for early detection of ovarian cancer." Mol Biol Rep. September 11, 2026. PMID 42726150. https://doi.org/10.1007/s11033-026-12750-6 (open access, review of DNA methylation biomarkers for early detection)

Related citations, access restricted:

84. Li Z, et al. "Development and validation of a serum peptidomic signature for early detection of asymptomatic ovarian cancer: A multi-center prospective study." Cell Rep Med. September 2026. PMID 42664958. https://doi.org/10.1016/j.xcrm.2026.103014 (restricted license, CC BY-NC-ND 4.0)

85. Chapman GC, et al. "Leveraging artificial intelligence in the early detection of ovarian cancer: Development and validation of a risk prediction model." Gynecol Oncol. September 2026. PMID 42664614. https://doi.org/10.1016/j.ygyno.2026.08.012 (subscription access)

86. Elgedawy GA, et al. "Beyond CA-125: circulating cell-free DNA as the next-generation biomarker in ovarian malignancy." BMC Cancer. September 8, 2026. PMID 42728613. https://doi.org/10.1186/s12885-026-15967-7 (restricted license, CC BY-NC-ND 4.0)

87. Ren CF, et al. "Diagnosis of ovarian cancer using multiple biomarkers of CA 125, CA153, CA 19-9, CEA, HE4 and ROMA index." Ann Biol Clin (Paris). September 10, 2026. PMID 42698297. https://doi.org/10.1684/abc.2026.2060 (subscription access)

88. Li DM, et al. "Evaluating the diagnostic performance of exosome biomarkers for the detection of ovarian cancer: a systematic review and meta-analysis." Eur J Obstet Gynecol Reprod Biol. September 2026. PMID 42497533. https://doi.org/10.1016/j.ejogrb.2026.115323 (subscription access)

89. Lange JM, et al. "Can ovarian cancer screening work? A secondary analysis of the UK collaborative trial of ovarian cancer screening." Br J Cancer. September 2026. PMID 42288686. https://doi.org/10.1038/s41416-026-03490-2 (license unconfirmed)

90. Tong A, et al. "Optimizing the MRI Pelvis Protocol for O-RADS MRI." Radiographics. September 2026. PMID 42560824. https://doi.org/10.1148/rg.250197 (subscription access)

91. Liu L, et al. "A multimodal MRI radiomics model for distinguishing borderline from malignant ovarian epithelial tumors." Clin Transl Oncol. September 2026. PMID 42310186. https://doi.org/10.1007/s12094-026-04464-9 (subscription access)

92. Alruwaili MM, et al. "Gasdermin proteins as pyroptosis-based biomarkers in ovarian cancer: Diagnostic and prognostic utility." Clin Chim Acta. September 2026. PMID 42251925. https://doi.org/10.1016/j.cca.2026.121152 (license unconfirmed)

93. Ciccarone F, et al. "Differentiating high- and low-grade serous ovarian carcinoma using radiomics: a pilot study." Ultrasound Obstet Gynecol. September 13, 2026. PMID 42733285. https://doi.org/10.1002/uog.70331 (license unconfirmed)

Hereditary risk: genetic counseling, community outreach, and preventive surgery

Directly referenced:

94. Gootzen TA, et al. "Menopause-related quality of life 5 years after salpingectomy with delayed oophorectomy vs salpingo-oophorectomy." J Natl Cancer Inst. September 1, 2026. PMID 41955317. https://doi.org/10.1093/jnci/djag110

95. Montoya DM, et al. "Community-Based Hereditary Breast and Ovarian Cancer Family History Assessment and Genetic Testing among Spanish-Speaking Hispanic/Latina Women in California." Cancer Res Commun. September 1, 2026. PMID 42641171. https://doi.org/10.1158/2767-9764.CRC-26-0046

96. Shaalan W, et al. "Bridging the gap between guidelines and practice: genetic counseling uptake and barriers in patients with ovarian malignancies." BMC Womens Health. September 29, 2026. PMID 42811314. https://doi.org/10.1186/s12905-026-04940-y

Additional open-access citations:

97. Imyanitov E, et al. "Breast-Ovarian Hereditary Cancer Syndrome: Beyondand." Curr Oncol. September 14, 2026. PMID 42782902. https://doi.org/10.3390/curroncol33090556 (open access, review of hereditary genes beyond BRCA1/2)

Related citations, access restricted:

98. Gopal S. "Bridging the BRCA1/2 variant previvor gap in health care." JAAPA. September 24, 2026. PMID 42779039. https://doi.org/10.1097/01.JAA.0000000000000423 (subscription access)

99. Amann N, et al. "Risk-reducing salpingo-oophorectomy in patients with gBRCA-mutated breast cancer." Arch Gynecol Obstet. September 28, 2026. PMID 42804048. https://doi.org/10.1007/s00404-026-08581-2 (license unconfirmed)

100. Viveros-Carreño D, et al. "From genetic testing to prevention: an integrated clinical pathway for hereditary risk assessment in tubo-ovarian cancer." Int J Gynecol Cancer. September 2026. PMID 42617415. https://doi.org/10.1016/j.ijgc.2026.104898 (subscription access)

101. Bounous VE, et al. "Hormone replacement therapy in healthy BRCA1 and 2 mutation carriers after risk-reducing salpingo-oophorectomy: A 5 Ws and 2 Hs practitioner toolkit." Maturitas. September 2026. PMID 42575068. https://doi.org/10.1016/j.maturitas.2026.108982 (subscription access)

102. Oliveira AF, et al. "Brazilian Society of Surgical Oncology Analysis in Cost-Effectiveness of Population-Based BRCA Testing for Ovarian Cancer in the Public Health System." J Surg Oncol. September 2026. PMID 42478334. https://doi.org/10.1002/jso.70302 (free to read, no reuse license)

103. Goto Y, et al. "Towards sustainable hereditary breast and ovarian cancer surveillance: insights from a single-center survey." J Hum Genet. September 2026. PMID 42410220. https://doi.org/10.1038/s10038-026-01491-w (subscription access)

104. Senter L, et al. "The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial." Cancer Prev Res (Phila). September 1, 2026. PMID 42339534. https://doi.org/10.1158/1940-6207.CAPR-26-0044 (free to read, no reuse license)

105. Haroun O, et al. "Genetic counseling services for hereditary breast and ovarian cancer: patients' experience and satisfaction with different service models." Eur J Hum Genet. September 2026. PMID 41699267. https://doi.org/10.1038/s41431-026-02031-y (free to read, no reuse license)

106. Pradutchon S, et al. "The uptake rate of risk-reducing salpingo-oophorectomy among Thai women with breast cancer and germline BRCA pathogenic or likely pathogenic variants." Eur J Cancer Prev. September 2026. PMID 41562867. https://doi.org/10.1097/CEJ.0000000000001005 (subscription access)

107. Zattarin E, et al. "Clinical implications of the type and genomic location of pathogenic BRCA1 and BRCA2 variants in hereditary breast and ovarian cancer." Crit Rev Oncol Hematol. September 29, 2026. PMID 42810557. https://doi.org/10.1016/j.critrevonc.2026.105633 (license unconfirmed)

Less common subtypes, including low-grade serous, clear cell, and endometriosis-associated cancers, are getting a closer look

Directly referenced:

108. Flethe C, et al. "Clinical relevance of CA125 in low-grade serous ovarian cancer: a retrospective multi-center JAGO/NOGGO study." Int J Gynecol Cancer. September 2026. PMID 42248787. https://doi.org/10.1016/j.ijgc.2026.104760

109. Hellberg P, et al. "p53 Normal and p53 Abnormal Clear Cell Ovarian Carcinomas: Clinical Characteristics and Biomarker Profiles." Int J Gynecol Pathol. September 2026. PMID 42206767. https://doi.org/10.1097/PGP.0000000000001191

110. Sung YW, et al. "Platinum sensitivity drives prognosis in endometriosis-associated ovarian carcinoma compared with high-grade serous ovarian carcinoma: Insights from a 10-year retrospective study." Taiwan J Obstet Gynecol. September 2026. PMID 42642157. https://doi.org/10.1016/j.tjog.2025.11.029

111. Piacenti I, et al. "Risk, Prevalence and Survival Outcomes of Ovarian Cancer in Women With Endometriosis: The Endocancer Systematic Review and Meta-Analysis." J Minim Invasive Gynecol. September 2026. PMID 42102910. https://doi.org/10.1016/j.jmig.2026.04.021

Related citations, access restricted:

112. Podder V, et al. "An evaluation of avutometinib in combination with defactinib for-mutated recurrent low-grade serous ovarian cancer." Expert Rev Anticancer Ther. September 2026. PMID 42059499. https://doi.org/10.1080/14737140.2026.2665840 (subscription access)

113. Zacholski EH, et al. "Response to Sotorasib in a patient with recurrent KRAS G12C-mutated low-grade serous ovarian cancer: a case report and literature review." Gynecol Oncol Rep. September 2, 2026. PMID 42756523. https://doi.org/10.1016/j.gore.2026.102203 (restricted license, CC BY-NC-ND 4.0)

114. Leone Roberti Maggiore U, et al. "Endometriosis and ovarian cancer: epidemiological evidence, molecular insights, and clinical decision-making." Hum Reprod Update. September 1, 2026. PMID 42143676. https://doi.org/10.1093/humupd/dmag011 (subscription access)

115. Dou Y, et al. "Integrative analysis and experiment validation of SLC12A8 as a biomarker for the malignant transition from endometriosis to endometriosis associated ovarian cancer." Funct Integr Genomics. September 15, 2026. PMID 42742760. https://doi.org/10.1007/s10142-026-02047-z (subscription access)

116. Hopp EE, et al. "A phase II study of androgen receptor inhibition by darolutamide in combination with leuprolide acetate and exemestane in recurrent adult-type ovarian granulosa cell tumor." Gynecol Oncol. September 2026. PMID 42574969. https://doi.org/10.1016/j.ygyno.2026.07.017 (free to read, no reuse license)

117. Pichatechaiyoot A, et al. "Menstrual Recovery and Reproductive Outcomes After Fertility-Sparing Surgery and Adjuvant Chemotherapy for Malignant Ovarian Germ Cell Tumors: A Retrospective Cohort Study." J Obstet Gynaecol Res. September 2026. PMID 42695620. https://doi.org/10.1111/jog.70462 (free to read, no reuse license)

118. Lee J, et al. "Successful Management of Ultra-high-risk Mixed Ovarian Germ Cell Tumor Using a Pediatric-inspired Intensive Chemotherapy Regimen: A Case Report." In Vivo. September 2026. PMID 42665409. https://doi.org/10.21873/invivo.14469 (free to read, no reuse license)

119. Sheng C, et al. "Development of a prediction model for recurrence in patients with malignant ovarian germ cell tumors undergoing fertility-sparing surgery: A multicenter retrospective study." Eur J Surg Oncol. September 2026. PMID 42424681. https://doi.org/10.1016/j.ejso.2026.111995 (subscription access)

120. Grove J, et al. "Cytologic Detection of Metastatic Immature Teratomas in Two Young Patients With Unique Presentations." Diagn Cytopathol. September 2026. PMID 42318909. https://doi.org/10.1002/dc.70162 (free to read, no reuse license)

121. Yoon JK, et al. "Physiologic Menstrual 18 F-FDG Uptake in Uterine Didelphys Mimicking Metastasis in a Patient With Ovarian Immature Teratoma." Clin Nucl Med. September 2026. PMID 42149926. https://doi.org/10.1097/RLU.0000000000006553 (subscription access)

122. Sood R, et al. "Role of ascitic and peritoneal fluid effusion cytology in predicting intraperitoneal metastasis of malignant ovarian germ cell tumors." J Am Soc Cytopathol. September 2026. PMID 42103533. https://doi.org/10.1016/j.jasc.2026.04.002 (subscription access)

123. Sullivan SM, et al. "Overlapping genetic etiology of pediatric and adult germ cell tumors." J Natl Cancer Inst. September 1, 2026. PMID 41941753. https://doi.org/10.1093/jnci/djag097 (free to read, no reuse license)

124. Smith LP, et al. "It Does Exist! Diagnosis and Management of Thyroid Carcinomas Originating in Struma Ovarii." Clin Lab Med. September 2026. PMID 42526970. https://doi.org/10.1016/j.cll.2026.06.006 (subscription access)

125. Kinloch M, et al. "Mucinous Carcinomas of the Gastrointestinal and Gynecologic Tracts-Diagnostic Challenges in Overlapping Pathologies." Surg Pathol Clin. September 2026. PMID 42508932. https://doi.org/10.1016/j.path.2026.02.010 (subscription access)

126. Smith C, et al. "Ovarian Mucinous Neoplasms Associated With Mesonephric-like Lesions: An Updated Study With Novel Pathologic Features." Am J Surg Pathol. September 2026. PMID 42199023. https://doi.org/10.1097/PAS.0000000000002573 (subscription access)

127. Alzayadneh E, et al. "HER2 and FOLR1 Expression in Mesonephric and Mesonephric-Like Adenocarcinomas in the Gynecologic Tract." Int J Gynecol Pathol. September 2026. PMID 42095344. https://doi.org/10.1097/PGP.0000000000001187 (subscription access)

128. Zhao W, et al. "Squamous cell carcinoma arising from ovarian mature cystic teratoma with concurrent cervical high-risk HPV infection and low-grade squamous intraepithelial lesion: a case report." BMC Womens Health. September 18, 2026. PMID 42823697. https://doi.org/10.1186/s12905-026-04834-z (restricted license, CC BY-NC-ND 4.0)

129. Shobeirian F, et al. "Multimodality imaging features of pediatric ovarian tumors: a pictorial essay." Pediatr Radiol. September 2026. PMID 42165857. https://doi.org/10.1007/s00247-026-06652-9 (subscription access)

Survivorship research looks at life during and after treatment

Directly referenced:

130. da Silva-Filho AL, et al. "Menopausal hormone therapy and comprehensive postmenopausal care in gynecologic cancer survivors: A position paper from the FIGO Committee on Women at Menopausal Age." Int J Gynaecol Obstet. September 2026. PMID 42483786. https://doi.org/10.1002/ijgo.71188

Related citations, access restricted:

131. Pang Y, et al. "Characteristics and influencing factors of demoralization in ovarian cancer: a latent profile analysis." Support Care Cancer. September 8, 2026. PMID 42709228. https://doi.org/10.1007/s00520-026-11162-3 (subscription access)

132. Qiu T, et al. "Prevalence Rates of Depression, Anxiety, and Suicidal Ideation in Patients with Ovarian cancer: A Systematic Review from 1977 to 2024." Int J Psychiatry Med. September 2026. PMID 40514047. https://doi.org/10.1177/00912174251350465 (subscription access)

133. Viveros-Carreño D, et al. "Low anterior resection syndrome and bowel dysfunction after ovarian cancer cytoreductive surgery: a narrative review." Int J Gynecol Cancer. September 23, 2026. PMID 42778470. https://doi.org/10.1016/j.ijgc.2026.105005 (subscription access)

134. Gunturi A, et al. "Palliative Care for Ovarian Cancer in Low- and Lower-Middle-Income Countries: A Scoping Review." JCO Glob Oncol. September 17, 2026. PMID 42753201. https://doi.org/10.1200/GO-25-00451 (license unconfirmed)

135. Morefu MG, et al. "An assessment of the prevalence of drug therapy problems and its associated factors among ovarian cancer patients at Kenyatta National Hospital." J Oncol Pharm Pract. September 2026. PMID 40239095. https://doi.org/10.1177/10781552251331479 (subscription access)

136. Rocque GB, et al. "Characterizing the Objective Time Spent on Health Care Activities in Clinic and at Home for Patients With Cancer." Cancer Med. September 2026. PMID 42747975. https://doi.org/10.1002/cam4.72277 (license unconfirmed)

137. Shin R, et al. "Supporting patient understanding of cervical and ovarian cancer: how well does AI perform?" Proc (Bayl Univ Med Cent). September 2026. PMID 42405834. https://doi.org/10.1080/08998280.2026.2694930 (free to read, no reuse license)

Epidemiology, Access & Health Disparities Research

Directly referenced:

138. Du Y, et al. "Recent patterns and trends in global ovarian cancer incidence and mortality in adolescents and young adults." J Gynecol Oncol. September 2026. PMID 42108736. https://doi.org/10.3802/jgo.2026.37.e106

139. Riese C, et al. "Incidence, prevalence, mortality and survival trends in women with endometrial-, ovarian- and cervical cancer in the Nordic countries (1980-2023) with focus on younger women (0-49 years old)." Gynecol Oncol. September 2026. PMID 42617581. https://doi.org/10.1016/j.ygyno.2026.08.014

Additional open-access citations:

140. Gersekowski K, et al. "Using administrative health data to ascertain ovarian cancer treatment information in Australia: a validation against medical records." Public Health Res Pract. September 24, 2026. PMID 42734015. https://doi.org/10.1071/PU25097 (open access, validating administrative data for treatment research, Australia)

141. Zheng P, et al. "Psychiatric disorders and gynecologic tumors: A 2-sample Mendelian randomization study of 20 exposure-outcome pairs." Medicine (Baltimore). September 18, 2026. PMID 42760730. https://doi.org/10.1097/MD.0000000000050669 (open access, psychiatric disorders and gynecologic cancer risk, genetic study)

Related citations, access restricted:

142. Huang C, et al. "Global, regional, and national burden of ovarian cancer from 1990 to 2021: Analysis of risk factors and prediction of trends in 2050." Medicine (Baltimore). September 25, 2026. PMID 42798067. https://doi.org/10.1097/MD.0000000000050828 (license unconfirmed)

143. Zhang X, et al. "Cervical, Uterine, and Ovarian Cancers in Chinese Women Aged 55 Years and Older: Burden, Temporal Trends, Risk Attribution, and Future Projections From the Global Burden of Disease Study 2021." J Obstet Gynaecol Res. September 2026. PMID 42755024. https://doi.org/10.1111/jog.70413 (subscription access)

144. Yin X, et al. "Geographic disparities, trial characteristics, and transparency of 3720 ovarian cancer clinical trials." J Cancer Policy. September 2026. PMID 42600890. https://doi.org/10.1016/j.jcpo.2026.100792 (subscription access)

145. Ferro C, et al. "Oncology Patients in Clinical Trials: A Health Care Cost Analysis." Am J Manag Care. September 1, 2026. PMID 42809499. https://doi.org/10.37765/ajmc.2026.90012 (license unconfirmed)

146. Tran PL, et al. "[Specificity in the management of gynecological cancers in French overseas departments]." Bull Cancer. September 2026. PMID 42425823. https://doi.org/10.1016/j.bulcan.2026.05.003 (subscription access)

147. Gatta G, et al. "Cancer Patients Mortality From Other Causes: A European Population-Based Study." Cancer Med. September 2026. PMID 42734108. https://doi.org/10.1002/cam4.72266 (restricted license, CC BY-NC-ND 4.0)

148. Townsend MK, et al. "A Multistate Survival Model to Identify Risk Factors for Lethal Ovarian Cancer." Cancer Epidemiol Biomarkers Prev. September 1, 2026. PMID 42340350. https://doi.org/10.1158/1055-9965.EPI-26-0152 (free to read, no reuse license)

149. Mongiovi JM, et al. "Ovarian cancer tumor immune profiles associated with intrauterine device and oral contraceptive use." Br J Cancer. September 2026. PMID 42365137. https://doi.org/10.1038/s41416-026-03508-9 (license unconfirmed)

150. Liu BQ, et al. "2-Ethylhexyl diphenyl phosphate exposure is associated with poorer overall survival in advanced high-grade serous ovarian cancer: Integrated epidemiological and experimental evidence implicating the ITGB1-FAK-AKT axis." Ecotoxicol Environ Saf. September 2026. PMID 42580256. https://doi.org/10.1016/j.ecoenv.2026.120645 (restricted license, CC BY-NC-ND 4.0)

General & Basic-Science Research

Directly referenced:

151. Pellarin I, et al. "CDK12/13 inhibition overcomes platinum resistance by impairing RNA metabolism." Signal Transduct Target Ther. September 3, 2026. PMID 42686681. https://doi.org/10.1038/s41392-026-02932-w

152. Venkatachalam A, et al. "BCLXblockade rewires cell fate to overcome PARP inhibitor resistance in ovarian cancer." Signal Transduct Target Ther. September 21, 2026. PMID 42764286. https://doi.org/10.1038/s41392-026-02870-7

Additional open-access citations:

153. Dehghani-Ghobadi Z, et al. "Profiling tumor immune microenvironment of epithelial ovarian carcinoma." Oncoimmunology. September 10, 2026. PMID 42721374. https://doi.org/10.1080/2162402X.2026.2722470 (open access, immune landscape across ovarian cancer histotypes)

154. Swenson H, et al. "Non-parametric differential methylation analysis characterizes histotype-specific promoter regions in epithelial ovarian cancer." Epigenetics. September 2, 2026. PMID 42683873. https://doi.org/10.1080/15592294.2026.2720990 (open access, DNA methylation patterns by histotype)

155. Khazem H, et al. "BCAM-AKT2 fusion protein promotes unfolded protein response driven oncogenic signaling in SKOV3 epithelial ovarian cancer cell line." PLoS One. September 25, 2026. PMID 42789557. https://doi.org/10.1371/journal.pone.0357882 (open access, BCAM-AKT2 fusion protein, laboratory study)

156. Zhu J, et al. "Drug delivery systems modified with cell-penetrating peptide tat and folate reverse multidrug resistance in ovarian and colorectal cancer by endocytosis-mediated efficient uptake and energy production reduction." Biomed Mater. September 25, 2026. PMID 42665012. https://doi.org/10.1088/1748-605X/aea048 (open access, nanoparticles to overcome drug resistance, laboratory study)

157. Liu X, et al. "An SPP1-centered immune-parenchymal communication axis links macrophage heterogeneity to ovarian cancer prognosis." Front Immunol. September 22, 2026. PMID 42839972. https://doi.org/10.3389/fimmu.2026.1949243 (open access, macrophage signaling and prognosis, bioinformatics)

158. Che X, et al. "CD28-ICOS costimulation enhances the therapeutic efficacy of L1CAM-targeted CAR-T cells against ovarian and gastric cancers." J Immunother Cancer. September 18, 2026. PMID 42759981. https://doi.org/10.1136/jitc-2025-014131 (open access, L1CAM-targeted CAR-T cells, preclinical)

159. Tian Z, et al. "G2/M Checkpoint Dependency in High-Grade Serous Tubo-Ovarian Carcinoma: Mechanisms and Therapeutic Implications." Genes (Basel). September 17, 2026. PMID 42793028. https://doi.org/10.3390/genes17091135 (open access, review of G2/M checkpoint dependency)

160. Jin Y, et al. "Translational Progress of Inorganic Nanotheranostic Platforms for Gynecologic Malignancies: A Narrative Review of Endometrial, Ovarian, and Cervical Cancer Focusing on Fertility Preservation, Biosafety, and Industrial Translation." Int J Nanomedicine. September 16, 2026. PMID 42769022. https://doi.org/10.2147/IJN.S642254 (open access, review of nanomedicine across gynecologic cancers)

161. Alsamman K. "Epigenetic mechanisms and clinical translation in ovarian cancer: from molecular pathways to precision therapy." Biosci Rep. September 16, 2026. PMID 42638590. https://doi.org/10.1042/BSR20250409 (open access, review of epigenetic mechanisms)

162. Dai Z, et al. "TMEM61 Promotes Malignant Behaviors and Maintains Genomic Stability in Ovarian Cancer Cells." Front Biosci (Landmark Ed). September 15, 2026. PMID 42811982. https://doi.org/10.31083/FBL54612 (open access, TMEM61 gene, laboratory study)

163. Thiel J, et al. "The FAP × CD3 bispecific antibody OMTX305 induces T cell-mediated antitumor effects in patient-derived ex vivo models of solid tumors." Sci Adv. September 11, 2026. PMID 42726846. https://doi.org/10.1126/sciadv.aee2124 (open access, FAP x CD3 bispecific antibody, patient-derived models)

164. Gordeeva AI, et al. "Protein Variability Patterns in Ovarian Serous Carcinoma." Int J Mol Sci. September 9, 2026. PMID 42794441. https://doi.org/10.3390/ijms27188012 (open access, protein variability patterns, proteomics)

165. Karalok MH, et al. "Comparative Effects of Pairwise Combinations of Carboplatin, Everolimus, and Astaxanthin on Cell Viability, Migration, and Inflammatory Biomarkers in SKOV3 Ovarian Cancer Cells." Int J Mol Sci. September 8, 2026. PMID 42794426. https://doi.org/10.3390/ijms27187995 (open access, drug combinations in cell lines)

166. Moffitt LR, et al. "Comparative Characterisation of Subcutaneous, Intraperitoneal and Intrabursal OVCAR3 Models." Int J Mol Sci. September 8, 2026. PMID 42794413. https://doi.org/10.3390/ijms27187981 (open access, comparison of mouse tumor models)

167. Peng Z, et al. "Targeted Modulation of Abundant Proteins Enhances Proteomic Profiling of Ovarian Cancer Ascites: A Pilot Technical Workflow Comparison." J Proteome Res. September 4, 2026. PMID 42695897. https://doi.org/10.1021/acs.jproteome.6c00382 (open access, ascites proteomics methods, pilot)

168. Chitoh AM, et al. "Mechanistic Insights into-Induced Apoptosis in Ovarian Cancer Cells via the Intrinsic Pathway." Int J Mol Sci. September 3, 2026. PMID 42737783. https://doi.org/10.3390/ijms27177887 (open access, plant extract and apoptosis, laboratory study)

169. Özcan H, et al. "Assessment of the Targeted Therapeutic Potential of Naringenin-Benzyl Piperazine Derivatives on Hypoxia-Induced JAK/STAT Pathway in Breast and Ovarian Cancers." Arch Pharm (Weinheim). September 2026. PMID 42768853. https://doi.org/10.1002/ardp.70339 (open access, naringenin derivatives, laboratory study)

170. Liu J, et al. "Single-Cell Transcriptomic Analysis Reveals Ferroptosis-Related Signatures and Tumor Microenvironment Heterogeneity in Epithelial Ovarian Cancer." Cancer Med. September 2026. PMID 42723230. https://doi.org/10.1002/cam4.72257 (open access, ferroptosis signatures, single-cell analysis)

171. Mikeska RG, et al. "Inhibiting CXCR2 Remodels the Tumor Microenvironment and Blunts Tumor Progression and Dissemination of High-Grade Serous Carcinoma." Cancer Res Commun. September 1, 2026. PMID 42617051. https://doi.org/10.1158/2767-9764.CRC-26-0408 (open access, CXCR2 inhibition, preclinical)

172. Ren B, et al. "Cell-Type-Resolved Proteomics Reveals Distinct Immune and Metabolic Programs Between Primary and Recurrent Ascites in HGSOC." Proteomics Clin Appl. September 2026. PMID 42610661. https://doi.org/10.1002/prca.70053 (open access, ascites proteomics at diagnosis and recurrence, pilot)

173. Jiang Q, et al. "Targeting HDAC and proteostasis to eradicate quiescent cancer cells." Cancer Gene Ther. September 2026. PMID 42595792. https://doi.org/10.1038/s41417-026-01067-y (open access, targeting dormant cancer cells, preclinical)

174. Li H, et al. "PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR-T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy." Adv Sci (Weinh). September 2026. PMID 42574087. https://doi.org/10.1002/advs.76994 (open access, PARP inhibitor bridging before CAR-T cells, preclinical)

175. Suriya S, et al. "PARP inhibition induces a redox-dependent dormant reservoir vulnerable to disulfiram in high-grade serous ovarian cancer." Biomed Pharmacother. September 2026. PMID 42546410. https://doi.org/10.1016/j.biopha.2026.119821 (open access, PARP inhibitor dormancy and disulfiram, laboratory study)

176. Conant A, et al. "Interferon beta drives therapy resistance in a patient-derived model of high-grade serous ovarian cancer." Mol Oncol. September 2026. PMID 42429323. https://doi.org/10.1002/1878-0261.70305 (open access, interferon beta and therapy resistance, patient-derived model)

177. Panagopoulos I, et al. "Fusion gene heterogeneity and kinase enrichment in high-grade serous carcinomas." Neoplasia. September 2026. PMID 42349107. https://doi.org/10.1016/j.neo.2026.101332 (open access, fusion genes in high-grade serous carcinoma)

178. Saleh A, et al. "CCDC80 suppresses high-grade serous ovarian cancer migration via negative regulation of B7-H3." Mol Oncol. September 2026. PMID 42011738. https://doi.org/10.1002/1878-0261.70235 (open access, CCDC80 and B7-H3, preclinical)

179. Tandaric L, et al. "Establishment of a humanized patient-derived xenograft mouse model of high-grade serous ovarian cancer for preclinical evaluation of combination immunotherapy." Mol Oncol. September 2026. PMID 41830513. https://doi.org/10.1002/1878-0261.70231 (open access, humanized mouse model for immunotherapy testing)

180. Bielesch S, et al. "Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high-grade serous ovarian cancer." Mol Oncol. September 2026. PMID 41714116. https://doi.org/10.1002/1878-0261.70227 (open access, keratin 19 as a prognostic marker)

181. Wang W, et al. "Engineered extracellular vesicles enriched with the miR-214/199a cluster enhance the efficacy of chemotherapy in ovarian cancer." Mol Oncol. September 2026. PMID 41685760. https://doi.org/10.1002/1878-0261.70224 (open access, engineered extracellular vesicles with chemotherapy, preclinical)

182. Marques LF, et al. "Beyond Tumor-Intrinsic STAT3: Integrating Metabolic and Immune Communication in the Tumor Microenvironment of Cervical, Ovarian, and Endometrial Cancers." Cancers (Basel). September 14, 2026. PMID 42794927. https://doi.org/10.3390/cancers18182960 (open access, review of STAT3 in gynecologic cancers)

183. Chuwa AH, et al. "Immunometabolic interactions in gynecologic cancers: Mechanisms, biomarkers, and therapeutic implications." J Int Med Res. September 16, 2026. PMID 42750153. https://doi.org/10.1177/03000605261476189 (open access, review of immunometabolism in gynecologic cancers)

184. Tang ZJ. "Retraction note: Unlocking the future: Mitochondrial genes and neural networks in predicting ovarian cancer prognosis and immunotherapy response." World J Clin Oncol. September 24, 2026. PMID 42820124. https://doi.org/10.5306/wjco.124428 (open access, retraction notice for an earlier prognostic modeling study)

Related citations, access restricted:

185. Chen Y, et al. "Flavonoids as promising natural therapeutics in ovarian cancer treatment: A comprehensive review." J Steroid Biochem Mol Biol. September 4, 2026. PMID 42697337. https://doi.org/10.1016/j.jsbmb.2026.107116 (subscription access)

186. Chen H, et al. "Ginsenoside Rg2 inhibits the cell viability of cisplatin-resistant epithelial ovarian cancer by suppressing CACNA1G-mediated calcium signaling." Toxicol Appl Pharmacol. September 11, 2026. PMID 42727823. https://doi.org/10.1016/j.taap.2026.118031 (subscription access)

187. Hussein Z, et al. "Identification of Highly Cytotoxic Antisense Oligonucleotides Targeting Essential Genes in Human Ovarian and Lung Cancer Cells." Chembiochem. September 28, 2026. PMID 42801750. https://doi.org/10.1002/cbic.70544 (subscription access)

188. Guo Y, et al. "Hirudin suppresses ovarian cancer cell proliferation and glycolysis through inhibiting the NF-κB/HK3 axis." Gene. September 2026. PMID 42177920. https://doi.org/10.1016/j.gene.2026.150233 (subscription access)

189. Abulajiang Y, et al. "Role of BTLA in ovarian cancer and its clinical prognostic significance based on multi-omics analysis." J Ovarian Res. September 17, 2026. PMID 42754905. https://doi.org/10.1186/s13048-026-02231-6 (restricted license, CC BY-NC-ND 4.0)

190. Yang S, et al. "Ion channel TRPML2 (MCOLN2) promotes ovarian cancer metastasis and chemoresistance." Biochem Biophys Res Commun. September 2026. PMID 42485795. https://doi.org/10.1016/j.bbrc.2026.154288 (subscription access)

191. Li C, et al. "Hypoxia-repressed lncRNA ZNF213-AS1 restrains p65-driven epithelial-mesenchymal transition in ovarian cancer." Biochem Biophys Res Commun. September 2026. PMID 42468178. https://doi.org/10.1016/j.bbrc.2026.154309 (subscription access)

192. Solomon N, et al. "Stromal-Immune Interactions Promote Immune Suppression in Intraperitoneal Metastasis of Ovarian Carcinoma." Cancer Res. September 15, 2026. PMID 42466975. https://doi.org/10.1158/0008-5472.CAN-25-2439 (subscription access)

193. Kul Karadenizli P, et al. "Synthesis and biological evaluation of 6,9-disubstituted purine analogues inducing autophagy-mediated apoptosis and potentiating carboplatin response in high-grade serous ovarian cancer." Bioorg Chem. September 2026. PMID 42391813. https://doi.org/10.1016/j.bioorg.2026.110197 (subscription access)

194. Zhao C, et al. "CCL19-armed oncolytic adenovirus synergizes with CCR7-expressing CAR-T cells to suppress ovarian tumor growth." Int Immunopharmacol. September 2026. PMID 42250288. https://doi.org/10.1016/j.intimp.2026.116980 (subscription access)

195. Boccarelli A, et al. "Identification of New Putative Autotaxin Inhibitors via Structure-Based Virtual Screening and Evaluation of Their Antiproliferative Properties Against Ovarian and Breast Cancer Cells." ChemMedChem. September 14, 2026. PMID 42675576. https://doi.org/10.1002/cmdc.70474 (free to read, no reuse license)

196. Heidemann S, et al. "A pro-inflammatory metastasis-associated macrophage subset induces tumor-promoting mesothelial cell conversion in ovarian cancer via IL-1α secretion." Cell Death Dis. September 12, 2026. PMID 42731998. https://doi.org/10.1038/s41419-026-09280-1 (free to read, no reuse license)

197. Tong X, et al. "A 177Lu-Labeled Circular Bivalent Aptamer for PTK7-Targeting Radionuclide Therapy in Ovarian Cancer and Orthotopic Hepatoblastoma." J Med Chem. September 10, 2026. PMID 42720498. https://doi.org/10.1021/acs.jmedchem.6c00687 (subscription access)

198. Corn D, et al. "Bright rRNA-Associated Merocyanine Probes Highlight Tumor Extensions in Ovarian Cancer." J Med Chem. September 10, 2026. PMID 42720477. https://doi.org/10.1021/acs.jmedchem.6c01028 (subscription access)

199. Khalili HS, et al. "Senescence-associated mitochondrial dysfunction as a therapeutic target in ovarian cancer: Challenges and opportunities." Eur J Pharmacol. September 2026. PMID 42594984. https://doi.org/10.1016/j.ejphar.2026.179250 (subscription access)

200. Miao Z, et al. "Bacteria-Based Ammunition for Cascade-Amplified Chemoimmunotherapy of Ovarian Cancer." Nano Lett. September 9, 2026. PMID 42715039. https://doi.org/10.1021/acs.nanolett.6c02787 (subscription access)

201. Shahnazi E, et al. "Birinapant enhances cisplatin sensitivity in epithelial ovarian cancer through modulation of apoptotic and survival signaling pathways." Cancer Chemother Pharmacol. September 8, 2026. PMID 42709209. https://doi.org/10.1007/s00280-026-04938-1 (subscription access)

202. Wang Y, et al. "Ovarian cancer proteomic landscape changes across different pathological stages and biomarker-sets identified with integrative multiomics analysis." Front Endocrinol (Lausanne). September 7, 2026. PMID 42769152. https://doi.org/10.3389/fendo.2026.1898210 (free to read, no reuse license)

203. Larsson E, et al. "Integrating Tumor Targeting and Half-Life Extension into a Dual-Surfaced Single-Domain ADAPT Protein." Mol Pharm. September 7, 2026. PMID 42704121. https://doi.org/10.1021/acs.molpharmaceut.6c00683 (license unconfirmed)

204. Tian N, et al. "VEGFR2-targeted NIR-II fluorescent probe for precise imaging and surgical navigation of ovarian cancer." Bioorg Chem. September 2026. PMID 42184579. https://doi.org/10.1016/j.bioorg.2026.110017 (subscription access)

205. Aleksandrovic E, et al. "Tumor-intrinsic IFNγ signaling and niche adaptation drive early colonization in ovarian cancer metastasis." Nat Commun. September 3, 2026. PMID 42834039. https://doi.org/10.1038/s41467-026-77222-8 (restricted license, CC BY-NC-ND 4.0)

206. Guo S, et al. "Redirected T-cell cytotoxicity identifies BRD9-PTGES axis as an immune-sensitising vulnerability in ovarian cancer." Biochem Biophys Res Commun. September 2026. PMID 42349121. https://doi.org/10.1016/j.bbrc.2026.154180 (subscription access)

207. Huo C, et al. "VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer." Cancer Immunol Res. September 2, 2026. PMID 42390478. https://doi.org/10.1158/2326-6066.CIR-25-1118 (restricted license, CC BY-NC-ND 4.0)

208. Yang G, et al. "PRMT5 Inhibition by SCR-6920 Downregulates HIF-1α and Exhibits Synergistic Antitumor Activity with Bevacizumab in Ovarian Cancer." Mol Cancer Ther. September 2, 2026. PMID 42012942. https://doi.org/10.1158/1535-7163.MCT-25-1105 (subscription access)

209. Huang TT, et al. "DHX9 Inhibition Enhances Paclitaxel Sensitivity by Inducing Mitotic Failure in Ovarian and Endometrial Cancers." Mol Cancer Ther. September 2, 2026. PMID 41873535. https://doi.org/10.1158/1535-7163.MCT-25-1196 (free to read, no reuse license)

210. Pushparaj PN, et al. "Deciphering the Dysregulated Pathways and Candidate Therapeutic Compounds for Primary Ovarian Cancer Using Whole Transcriptomics Data and Next Generation Knowledge Discovery Strategies." J Cell Mol Med. September 2026. PMID 42769006. https://doi.org/10.1111/jcmm.71356 (license unconfirmed)

211. Uehara T, et al. "Prognostic Impact of Serum microRNA Profiles on the Progression-Free Survival of Patients With High-Grade Serous Ovarian Cancer Receiving Neoadjuvant Chemotherapy." J Obstet Gynaecol Res. September 2026. PMID 42754539. https://doi.org/10.1111/jog.70500 (subscription access)

212. Koyanagi T, et al. "Progesterone Is Associated With Increased Vasohibin-2 Expression, Tubulin Detyrosination, and Paclitaxel Sensitivity in PR-Negative Ovarian Cancer Cells." Cancer Rep (Hoboken). September 2026. PMID 42702875. https://doi.org/10.1002/cnr2.70681 (license unconfirmed)

213. Justino IA, et al. "Brazilian Red Propolis Nanoparticles: In Vitro Anticancer Effects in Female-Associated Malignancies and In Vivo Toxicity in an Alternative Model." J Biomed Mater Res A. September 2026. PMID 42695471. https://doi.org/10.1002/jbm.a.70124 (license unconfirmed)

214. Rodighiero L, et al. "Expanding the scope of platinum-NHC complexes:-Pt(II) and Pt(0) architectures for ovarian cancer treatment." Dalton Trans. September 1, 2026. PMID 42622541. https://doi.org/10.1039/d6dt01513a (subscription access)

215. Ouyang X, et al. "Nicotinamide mononucleotide potentiates the anti-tumor efficacy of CAR-NK cell therapy targeting MSLN in ovarian cancer." Cancer Gene Ther. September 2026. PMID 42595793. https://doi.org/10.1038/s41417-026-01071-2 (subscription access)

216. Aal MCE, et al. "Three-dimensional cell cultures as an in vitro tool for ovarian cancer modeling and natural product discovery." Biomed Pharmacother. September 2026. PMID 42537397. https://doi.org/10.1016/j.biopha.2026.119823 (license unconfirmed)

217. Yang X, et al. "PACT Inhibits Malignant Biological Behavior of Ovarian Cancer Cells by Regulating TERT Expression." Mol Carcinog. September 2026. PMID 42462090. https://doi.org/10.1002/mc.70141 (free to read, no reuse license)

218. Lv S, et al. "Research on mechanism of exosome derived from EOC on promoting BMSCs and its autocrine effect in micro-environment through activating the VEGF-A/MAPK/ERK pathway." Pak J Pharm Sci. September 2026. PMID 42429285. https://doi.org/10.36721/PJPS.2026.39.9.241.1 (license unconfirmed)

219. Roy A. "Pathophysiological affair between protein kinase D and epithelial ovarian cancer: A roadmap towards translating the mechanism from bench to bedside." Biochim Biophys Acta Rev Cancer. September 2026. PMID 42425229. https://doi.org/10.1016/j.bbcan.2026.189661 (subscription access)

220. Liu Q, et al. "Micellar curcumol reprograms tumor-associated macrophages and reverses PARP inhibitor resistance in recurrent ovarian cancer." Phytomedicine. September 2026. PMID 42365697. https://doi.org/10.1016/j.phymed.2026.158461 (restricted license, CC BY-NC-ND 4.0)

221. Li Q, et al. "KPNA2 Drives Immunosuppression in Ovarian Cancer via CCL2/CCR2-Dependent MDSC Recruitment." Cancer Sci. September 2026. PMID 42331750. https://doi.org/10.1111/cas.70440 (license unconfirmed)

222. Bonci N, et al. "LINE-1 Deregulation in Ovarian Cancer: Implications for Diagnosis, Prognosis, and Therapeutic Targeting." Mol Diagn Ther. September 2026. PMID 42277396. https://doi.org/10.1007/s40291-026-00861-6 (subscription access)

223. Haghi SM, et al. "Brefeldin A induces apoptosis in cisplatin-resistant ovarian cancer cells independent of ABCC2-mediated drug efflux." Toxicol Appl Pharmacol. September 2026. PMID 42263956. https://doi.org/10.1016/j.taap.2026.117904 (subscription access)

224. Liu Y, et al. "STAT3 Inhibitor Suppresses CCL2-dependent Recruitment and M2 Polarization of Tumor-associated Macrophages to Enhance Antitumor Immunity in Ovarian Cancer." Appl Biochem Biotechnol. September 2026. PMID 42201615. https://doi.org/10.1007/s12010-026-05721-x (subscription access)

225. Yan Q, et al. "CCS facilitates the progression of ovarian cancer by suppressing ferroptotic cell death via the modulation of p53-mediated expression of SLC7A11 and GPX4." Acta Pharmacol Sin. September 2026. PMID 42144443. https://doi.org/10.1038/s41401-026-01816-7 (free to read, no reuse license)

226. Pan C, et al. "A novel hesperetin derivative DU12 targets cyclin-dependent kinase 17 (CDK17) to inhibit malignant progression of ovarian cancer." Biochem Pharmacol. September 2026. PMID 42142764. https://doi.org/10.1016/j.bcp.2026.118069 (subscription access)

227. Liu Y, et al. "Long-circulating ROS-responsive micelles for targeted eradication of cancer stem cells to inhibit tumor metastasis and recurrence." Biomater Adv. September 2026. PMID 42102603. https://doi.org/10.1016/j.bioadv.2026.214931 (subscription access)

228. Kader T, et al. "Spatial Integration of Protein and Chromosomal States Reveals Early Copy-Number Changes and Genotype-Associated Immune Neighborhoods in Serous Ovarian Cancer Evolution." Cancer Discov. September 1, 2026. PMID 41999663. https://doi.org/10.1158/2159-8290.CD-26-0171 (restricted license, CC BY-NC-ND 4.0)

229. Tarannum M, et al. "Spatially confined IL-12 programs CAR-NK through mTORC1 to coordinate antitumor immune networks." Cancer Discov. September 29, 2026. PMID 42810409. https://doi.org/10.1158/2159-8290.CD-26-0509 (subscription access)

230. Herranz-Ors C, et al. "A tumour-derived organoid biobank maps cancer gene dependencies." Nature. September 2026. PMID 42557320. https://doi.org/10.1038/s41586-026-10830-y (license unconfirmed)

231. Metcalfe TX, et al. "Activation of vitamin D signaling suppresses platinum-induced ovarian cancer stem cell plasticity." bioRxiv. September 23, 2026. PMID 42818011. https://doi.org/10.64898/2026.09.22.753468 (license unconfirmed)

232. Benbrook DM, et al. "Recent advancements in gynecologic cancer research: a SPORE investigators meeting report." J Natl Cancer Inst. September 15, 2026. PMID 42745474. https://doi.org/10.1093/jnci/djag319 (subscription access)

233. El Hajj H, et al. "Best original research presented at the 27th European Congress on Gynaecological Oncology: best of ESGO 2026." Int J Gynecol Cancer. September 2026. PMID 42541943. https://doi.org/10.1016/j.ijgc.2026.104875 (subscription access)

---

A note on how this digest was made: This edition was built by searching PubMed for papers published in September 2026, using targeted searches across the ovarian, fallopian tube, and peritoneal cancer landscape (PARP inhibitors, immunotherapy and antibody-drug conjugates, BRCA/HRD and hereditary risk, surgery, platinum resistance, early detection, subtypes, survivorship, and disparities), plus a dedicated qualitative search. Papers summarized in full are open access under a permitted license (CC0, CC BY, CC BY-SA, CC BY-ND, or CC BY-NC); on-topic papers under other licenses are listed by citation only. A companion methodology report, available separately, documents the full search-and-screening process and every paper reviewed.